Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Rauh

Gastroenterology Lexington, KY Medical Doctor

NPI 1548266976 CMS profile 341840

740 S Limestone Ste D201, Lexington, KY 40536

Open in the dashboard

General payments

$8,211

562 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$19,299 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Donald Rauh of Lexington, KY is reported in the CMS Open Payments database as having received $8,211 across 562 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $19,299 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2023 General $2,038 118
2022 General $1,883 123
2021 General $1,628 120
2020 General $1,291 101
2019 General $1,346 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Rauh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Donald Rauh were reported at $25. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Donald Rauh Gastroenterology median Middle half National median
2019 $1,346 $417 $126–$1,100 $163
2020 $1,291 $224 $74–$624 $114
2021 $1,628 $352 $106–$1,054 $132
2022 $1,883 $448 $129–$1,270 $149
2023 $2,038 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $25 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,258 245 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,202 89 payments
  3. Gilead Sciences, Inc. $540 28 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $532 36 payments
  5. Janssen Biotech, Inc. $481 32 payments
  6. Ironwood Pharmaceuticals, Inc $331 24 payments
  7. Intercept Pharmaceuticals, Inc. $200 12 payments
  8. Regeneron Healthcare Solutions, Inc. $191 5 payments
  9. Nestle HealthCare Nutrition Inc. $188 10 payments
  10. Celgene Corporation $170 11 payments
  11. Other $1,118 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,159 559 payments
  2. Education $51 3 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,029 79 payments
  2. CREON $905 67 payments
  3. LINZESS Gastroenterology $831 56 payments
  4. HUMIRA $803 81 payments
  5. STELARA $481 32 payments
  6. MAVYRET $440 35 payments
  7. RINVOQ $432 28 payments
  8. SKYRIZI $351 20 payments
  9. ENTYVIO $351 19 payments
  10. Linzess Gi $320 23 payments
  11. Other $3,161 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

219

Median for Gastroenterology: 569

Drug cost

$11,804

Median for Gastroenterology: $104,976

Branded share of claims

19.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mesalamine Generic 18 $9,397
Famotidine Generic 57 $646
Pantoprazole Sodium Generic 63 $635
Sucralfate Generic 16 $401
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $286
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 21 $222
Omeprazole Generic 22 $218

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$4,197

Medicare's payments for the services billed

Medicare patients

34

Average age 68

Services billed

269

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

562 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record